Pro: Should phosphate binders be used in chronic kidney disease stage 3-4? - Wikidata - awgldk - TriplyDB

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

http://www.wikidata.org/entity/Q38673170

about

Epidemiology of low-proteinuric chronic kidney disease in renal clinics Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned.

P2860

Q36284146-F8FE8EFD-0096-42C8-A19A-4D29916DE22E Q41038606-173C8B6A-EE29-42ED-884D-AE53F4BD2024

P2860

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

http://www.wikidata.org/entity/Q38673170

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

@en

type

label

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

@en

prefLabel

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

@en

P1433

Q38673170-539D1A36-4E59-4A8B-A11E-1410CE3DBD40

P1476

Q38673170-D5532088-CF96-48FF-897E-837757BFD068

P2093

Q38673170-E0CF4DC3-0055-42F5-BF1B-A1F051E27D75

P2860

Q38673170-05C986DF-E964-4889-B174-9F9B1AB7E747

Q38673170-19ECE207-AA60-4B83-9962-59A60A561D47

Q38673170-2A8BA3DC-641E-4E4B-A288-3B9893000FE3

Q38673170-328F5366-7290-42A9-B0B8-5EAB54C6620E

Q38673170-467F89E9-14B6-4570-BF39-9E1EEDFE8C92

Q38673170-54794DE2-7363-47F5-849C-0B61C872589C

Q38673170-5B4883D9-41C1-4E5B-9B05-7819215F8E8B

Q38673170-5C35D893-3901-4C11-AFB3-F1978F9F5671

Q38673170-5D5960C3-2F81-4995-8C2D-0523DF9472F1

Q38673170-664D909A-4BA9-4D40-9553-DF5ED3C64D60

P304

Q38673170-419AF276-AC60-431E-A5D6-EFFD790755CD

P31

Q38673170-1996E05B-76DA-4164-836D-BFE76E005954

P356

Q38673170-CFAF6710-7F84-46E4-8B6B-549C68DD9EAB

P407

Q38673170-7D963B50-EF70-4FB3-8FC3-2391D25664A2

P433

Q38673170-956F28A8-00D2-4255-9D42-45A532264830

P478

Q38673170-B075745A-B86F-425C-B5B2-D9F35B6C2CEC

P577

Q38673170-F046638A-B9DF-4AF8-8294-C4DFA1F9F33E

P698

Q38673170-5551E84C-659C-4E9F-850E-9D0944270BC5

P356

P1433

Nephrology Dialysis Transplantation

P1476

Pro: Should phosphate binders be used in chronic kidney disease stage 3-4?

@en

P2093

Antonio Bellasi

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphate regulation of vascular smooth muscle cell calcification

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

FGF23 induces left ventricular hypertrophy

Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study

Serum phosphate and mortality in patients with chronic kidney disease

Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction

Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets.

P304

184-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFV405

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26681748

http://www.w3.org/2001/XMLSchema#string